NuCana PLC
Change company Symbol lookup
Select an option...
NCNA NuCana PLC
NLY Annaly Capital Management Inc
TWTR Twitter Inc
UGAZ VelocityShares 3x Long Natural Gas ETN Linked to the S&P GSCI? Natural Gas Index ER
VXX iPath? Series B S&P 500? VIX Short-Term Futures? ETN
CMCSA Comcast Corp
CTL CenturyLink Inc
NGL NGL Energy Partners LP
SNH Senior Housing Properties Trust
SPH Suburban Propane Partners LP
Go

Health Care : Biotechnology |
Based in United KingdomCompany profile

NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The Company utilizes its ProTide technology to develop medicines to overcome cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline of products includes Acelarin, NUC-3373 and NUC-7738. Acelarin is a nucleotide analog and is a ProTide transformation of gemcitabine for the treatment of cancer. The Company is evaluating Acelarin in four clinical trials across several solid tumor indications. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil for the treatment of a wide range of cancers. NUC-3373 is in a Phase I trial for the potential treatment of a wide range of solid tumor cancers. NUC-7738 is a ProTide transformation of cordycepin, a novel nucleoside analog.

Price
Delayed
$6.78
Day's Change
0.13 (1.95%)
Bid
--
Ask
--
B/A Size
--
Day's High
7.14
Day's Low
6.50
Volume
(Heavy Day)

Today's volume of 62,635 shares is on pace to be much greater than NCNA's 10-day average volume of 44,874 shares.

62,635
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Social data discovery, filtering, and analysis provided by LikeFolio: © SwanPowers, LLC

Copyright © 2019. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.

TD Ameritrade provides access to social media platforms on an "as is" basis, and cannot guarantee that content from social media is always available, that it contains all content from the social media source, or that it contains the most recent or most relevant information from the source.